Janssen Biotech, Inc., a Johnson & Johnson company, has entered a worldwide collaboration and license agreement with TESARO, Inc., for exclusive rights to the investigational compound niraparib in prostate cancer. Niraparib is an orally administered poly polymerase (PARP) inhibitor, currently in late-stage development for metastatic breast cancer and ovarian cancer.   Janssen will have global rights and will be responsible for all development and commercialization activities for niraparib ...